10.21.2026
Alcon Acquires Neurotech Pharmaceuticals for $550 Million, Adding Encelto to Retina Portfolio
Alcon announced its acquisition of Neurotech Pharmaceuticals for $550 million, expanding its retina portfolio with Encelto (revakinagene taroretcel-lwey), the first and only FDA-approved treatment for adults with idiopathic macular telangiectasia type 2 (MacTel). The agreement includes potential additional payments contingent on commercial milestones.